Tyra Biosciences Inc TYRA

NAS: TYRA | ISIN: US90240B1061   17/05/2024
18,26 USD (-4,40%)
(-4,40%)   17/05/2024

9 mei 2024 · Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights · Persbericht

7 mei 2024 · Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors · Persbericht

19 maart 2024 · Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights · Persbericht

27 februari 2024 · Tyra Biosciences to Present at Upcoming Investor Conferences · Persbericht

7 februari 2024 · Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference · Persbericht

2 februari 2024 · Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing · Persbericht

1 februari 2024 · Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia · Persbericht

22 december 2023 · Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 · Persbericht

8 november 2023 · Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference · Persbericht

7 november 2023 · Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights · Persbericht

21 september 2023 · Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings · Persbericht

12 september 2023 · Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference · Persbericht

10 augustus 2023 · Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights · Persbericht

1 augustus 2023 · Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia · Persbericht

25 mei 2023 · Tyra Biosciences to Participate in Upcoming Investor Conferences · Persbericht

4 mei 2023 · Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights · Persbericht

29 maart 2023 · Tyra Biosciences to Participate in Upcoming Investor Conferences · Persbericht

22 maart 2023 · Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights · Persbericht

1 maart 2023 · Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia · Persbericht

22 februari 2023 · Tyra Biosciences to Present at Upcoming Investor Conferences · Persbericht

Mijn selecties